Rxsight, Inc. (RXST) Stock Price & Analysis
Rxsight, Inc. (RXST) fell 2.52% to USD 6.38 as of September 8, 2026 at 05:55 UTC, according to Nexqual real-time market data.
RXST last closed at USD 6.38; the session ranged USD 6.34–6.63 on volume of 561,298 shares. Market capitalization is —, with a 52-week range of USD 4.48–13.22 (NGM). Source: Nexqual, September 8, 2026 at 05:55 UTC.
Key Statistics (as of September 8, 2026 at 05:55 UTC)
| Price | USD 6.38 |
|---|---|
| Change | ▼ 2.52% (down) |
| Previous Close | USD 6.38 |
| Open | USD 6.38 |
| Day Range | USD 6.34 – 6.63 |
| 52-Week Range | USD 4.48 – 13.22 |
| Volume | 561,298 shares |
| Market Cap | — |
| Exchange | NGM |
Technical Analysis (RXST)
Nexqual's technical model rates RXST "NEUTRAL" based on 3 bullish and 2 bearish signals across 128 daily candles, as of September 8, 2026 at 05:55 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 50.73 (neutral) |
| vs SMA50 | Above (USD 6) |
| MACD | 0.19 (positive) |
From Rxsight, Inc.'s Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- In the U.S., the world's largest premium IOL market, 2025 premium procedures represented about 21% of all cataract procedures and generated approximately $860 million in revenue, a figure that is projected to grow at a 8.0% compound annual growth rate ("CAGR") by 2030, according to the Market Scope 2025 Premium Cataract Surgery Market Report.
- We are required to manufacture our products in compliance with the FDA's Quality Management System Regulation ("QMSR") (21 CFR Part 820 incorporating ISO 13485:2016), replacing the former Quality System Regulation.
- Our proprietary RxSight ® Light Adjustable Lens system ("RxSight system") is the first and only commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery.
- Our RxSight system is comprised of two key components, along with other intraoperative and postoperative accessories: • RxSight Light Adjustable Lens: The LAL is our proprietary IOL that can be adjusted postoperatively to improve uncorrected visual acuity.
Partnerships
- The facility fees associated with these codes include payment for a conventional IOL of up to $150.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SGHT | Sight Sciences, Inc. | USD 8.35 | ▼ 0.83% |
| TMCI | Treace Medical Concepts, Inc. | USD 4.81 | ▲ 2.34% |
| CTKB | Cytek Biosciences, Inc. | USD 4.7 | ▲ 0.21% |
| CVRX | CVRx, Inc. | USD 3.05 | ▼ 0.65% |
| RPID | Rapid Micro Biosystems, Inc. | USD 1.31 | ▼ 5.76% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:55 UTC. This page is informational and not investment advice.